Exact Sciences Corporation (EXAS)
USD 57.38
(-4.95%)
USD 57.38
(-4.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -204.14 Million USD | 67.26% |
| 2022 | -623.5 Million USD | -4.68% |
| 2021 | -595.62 Million USD | 29.81% |
| 2020 | -848.53 Million USD | -910.24% |
| 2019 | -83.99 Million USD | 52.04% |
| 2018 | -175.14 Million USD | -53.11% |
| 2017 | -114.39 Million USD | 31.59% |
| 2016 | -167.21 Million USD | -5.96% |
| 2015 | -157.8 Million USD | -57.73% |
| 2014 | -100.04 Million USD | -115.09% |
| 2013 | -46.51 Million USD | 11.27% |
| 2012 | -52.42 Million USD | -82.81% |
| 2011 | -28.67 Million USD | -148.14% |
| 2010 | -11.55 Million USD | -27.14% |
| 2009 | -9.08 Million USD | 6.69% |
| 2008 | -9.74 Million USD | 18.55% |
| 2007 | -11.95 Million USD | 7.4% |
| 2006 | -12.91 Million USD | 11.05% |
| 2005 | -14.52 Million USD | 21.61% |
| 2004 | -18.52 Million USD | 34.64% |
| 2003 | -28.34 Million USD | 5.16% |
| 2002 | -29.88 Million USD | -27.24% |
| 2001 | -23.48 Million USD | -97.64% |
| 2000 | -11.88 Million USD | -139.39% |
| 1999 | -4.96 Million USD | -38.73% |
| 1998 | -3.57 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -110.22 Million USD | -121.49% |
| 2024 Q2 | -15.8 Million USD | 85.66% |
| 2024 Q3 | -38.23 Million USD | -141.88% |
| 2023 FY | -204.14 Million USD | 67.26% |
| 2023 Q4 | -49.76 Million USD | -6367.76% |
| 2023 Q1 | -74.15 Million USD | 41.95% |
| 2023 Q2 | -81.02 Million USD | -9.27% |
| 2023 Q3 | 794 Thousand USD | 100.98% |
| 2022 Q2 | -166.06 Million USD | 8.22% |
| 2022 Q4 | -127.74 Million USD | 14.13% |
| 2022 FY | -623.5 Million USD | -4.68% |
| 2022 Q1 | -180.93 Million USD | 17.98% |
| 2022 Q3 | -148.76 Million USD | 10.42% |
| 2021 FY | -595.62 Million USD | 29.81% |
| 2021 Q1 | -31.16 Million USD | 92.87% |
| 2021 Q2 | -176.91 Million USD | -467.68% |
| 2021 Q3 | -166.93 Million USD | 5.64% |
| 2021 Q4 | -220.61 Million USD | -32.15% |
| 2020 Q3 | -219.88 Million USD | -155.26% |
| 2020 FY | -848.53 Million USD | -910.24% |
| 2020 Q4 | -436.81 Million USD | -98.65% |
| 2020 Q2 | -86.14 Million USD | 18.5% |
| 2020 Q1 | -105.69 Million USD | -235.6% |
| 2019 FY | -83.99 Million USD | 52.04% |
| 2019 Q4 | 77.94 Million USD | 292.65% |
| 2019 Q3 | -40.45 Million USD | -5.31% |
| 2019 Q1 | -83.05 Million USD | -53.89% |
| 2019 Q2 | -38.42 Million USD | 53.74% |
| 2018 Q2 | -36.38 Million USD | 7.7% |
| 2018 Q1 | -39.42 Million USD | -81.14% |
| 2018 Q3 | -45.36 Million USD | -24.67% |
| 2018 Q4 | -53.97 Million USD | -18.98% |
| 2018 FY | -175.14 Million USD | -53.11% |
| 2017 Q1 | -34.94 Million USD | 5.98% |
| 2017 FY | -114.39 Million USD | 31.59% |
| 2017 Q4 | -21.76 Million USD | 19.08% |
| 2017 Q3 | -26.89 Million USD | 12.64% |
| 2017 Q2 | -30.79 Million USD | 11.89% |
| 2016 Q2 | -44.76 Million USD | 5.7% |
| 2016 Q3 | -37.8 Million USD | 15.55% |
| 2016 Q1 | -47.47 Million USD | -18.71% |
| 2016 FY | -167.21 Million USD | -5.96% |
| 2016 Q4 | -37.17 Million USD | 1.67% |
| 2015 Q3 | -42.94 Million USD | -9.93% |
| 2015 Q4 | -39.99 Million USD | 6.88% |
| 2015 Q2 | -39.06 Million USD | -9.12% |
| 2015 Q1 | -35.8 Million USD | -10.35% |
| 2015 FY | -157.8 Million USD | -57.73% |
| 2014 Q1 | -16.1 Million USD | -32.18% |
| 2014 FY | -100.04 Million USD | -115.09% |
| 2014 Q4 | -32.44 Million USD | -1.2% |
| 2014 Q3 | -32.06 Million USD | -64.94% |
| 2014 Q2 | -19.43 Million USD | -20.67% |
| 2013 Q2 | -12.31 Million USD | -13.45% |
| 2013 Q3 | -11.16 Million USD | 9.37% |
| 2013 Q1 | -10.85 Million USD | 22.4% |
| 2013 Q4 | -12.18 Million USD | -9.19% |
| 2013 FY | -46.51 Million USD | 11.27% |
| 2012 Q3 | -12.95 Million USD | 12.7% |
| 2012 FY | -52.42 Million USD | -82.81% |
| 2012 Q2 | -14.83 Million USD | -39.37% |
| 2012 Q4 | -13.98 Million USD | -8.0% |
| 2012 Q1 | -10.64 Million USD | -7.48% |
| 2011 Q3 | -7.77 Million USD | -17.33% |
| 2011 FY | -28.67 Million USD | -148.14% |
| 2011 Q2 | -6.62 Million USD | -51.5% |
| 2011 Q1 | -4.37 Million USD | -22.39% |
| 2011 Q4 | -9.9 Million USD | -27.42% |
| 2010 Q1 | -2.12 Million USD | -14.56% |
| 2010 Q3 | -3.38 Million USD | -36.54% |
| 2010 Q4 | -3.57 Million USD | -5.65% |
| 2010 FY | -11.55 Million USD | -27.14% |
| 2010 Q2 | -2.47 Million USD | -16.62% |
| 2009 Q3 | -1.04 Million USD | 56.52% |
| 2009 FY | -9.08 Million USD | 6.69% |
| 2009 Q4 | -1.85 Million USD | -78.1% |
| 2009 Q2 | -2.39 Million USD | 37.64% |
| 2009 Q1 | -3.83 Million USD | -82.03% |
| 2008 Q3 | -3.01 Million USD | -43.52% |
| 2008 Q4 | -2.1 Million USD | 30.03% |
| 2008 FY | -9.74 Million USD | 18.55% |
| 2008 Q1 | -2.51 Million USD | 37.35% |
| 2008 Q2 | -2.1 Million USD | 16.6% |
| 2007 Q4 | -4.01 Million USD | 4.2% |
| 2007 FY | -11.95 Million USD | 7.4% |
| 2007 Q1 | -1.92 Million USD | 20.76% |
| 2007 Q2 | -1.82 Million USD | 4.95% |
| 2007 Q3 | -4.19 Million USD | -129.86% |
| 2006 Q4 | -2.42 Million USD | 21.41% |
| 2006 FY | -12.91 Million USD | 11.05% |
| 2006 Q1 | -4.16 Million USD | -54.47% |
| 2006 Q2 | -3.24 Million USD | 22.03% |
| 2006 Q3 | -3.08 Million USD | 5.02% |
| 2005 Q4 | -2.69 Million USD | 18.06% |
| 2005 FY | -14.52 Million USD | 21.61% |
| 2005 Q3 | -3.28 Million USD | 16.76% |
| 2005 Q2 | -3.95 Million USD | 13.83% |
| 2005 Q1 | -4.58 Million USD | -0.77% |
| 2004 Q1 | -5.29 Million USD | 7.35% |
| 2004 Q2 | -4.27 Million USD | 19.13% |
| 2004 Q4 | -4.55 Million USD | -3.34% |
| 2004 Q3 | -4.4 Million USD | -2.9% |
| 2004 FY | -18.52 Million USD | 34.64% |
| 2003 Q1 | -7.88 Million USD | -12.48% |
| 2003 FY | -28.34 Million USD | 5.16% |
| 2003 Q2 | -7.88 Million USD | -0.01% |
| 2003 Q3 | -6.86 Million USD | 12.96% |
| 2003 Q4 | -5.71 Million USD | 16.77% |
| 2002 Q1 | -7.58 Million USD | -14.16% |
| 2002 Q4 | -7 Million USD | 5.46% |
| 2002 Q2 | -7.87 Million USD | -3.81% |
| 2002 FY | -29.88 Million USD | -27.24% |
| 2002 Q3 | -7.41 Million USD | 5.86% |
| 2001 Q2 | -5.71 Million USD | -5.76% |
| 2001 Q4 | -6.64 Million USD | -15.98% |
| 2001 Q1 | -5.4 Million USD | 0.0% |
| 2001 FY | -23.48 Million USD | -97.64% |
| 2001 Q3 | -5.72 Million USD | -0.32% |
| 2000 FY | -11.88 Million USD | -139.39% |
| 1999 FY | -4.96 Million USD | -38.73% |
| 1998 FY | -3.57 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 12.191% |
| Prenetics Global Limited | -62.72 Million USD | -225.473% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -13087.92% |
| CareDx, Inc | -190.28 Million USD | -7.286% |
| Exagen Inc. | -23.68 Million USD | -761.788% |
| Inotiv, Inc. | -105.14 Million USD | -94.169% |
| Guardant Health, Inc. | -479.44 Million USD | 57.42% |
| Biodesix, Inc. | -52.14 Million USD | -291.495% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -7665.145% |
| Precipio, Inc. | -5.85 Million USD | -3387.938% |
| iSpecimen Inc. | -11.09 Million USD | -1739.265% |
| Natera, Inc. | -434.8 Million USD | 53.048% |
| Aspira Women's Health Inc. | -16.69 Million USD | -1123.182% |
| Standard BioTools Inc. | -74.65 Million USD | -173.453% |
| 23andMe Holding Co. | -666.7 Million USD | 69.379% |
| Castle Biosciences, Inc. | -57.46 Million USD | -255.252% |
| Personalis, Inc. | -108.29 Million USD | -88.51% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -130.726% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -1952.355% |
| OpGen, Inc. | -32.66 Million USD | -524.91% |
| T2 Biosystems, Inc. | -50.07 Million USD | -307.67% |
| Myriad Genetics, Inc. | -112 Million USD | -82.276% |
| ICON Public Limited Company | 612.33 Million USD | 133.339% |
| NeoGenomics, Inc. | -87.96 Million USD | -132.072% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -13087.92% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 124.158% |
| RadNet, Inc. | 3.04 Million USD | 6806.603% |
| MDxHealth SA | -43.1 Million USD | -373.664% |
| Psychemedics Corporation | -4.15 Million USD | -4814.516% |
| Illumina, Inc. | -1.16 Billion USD | 82.416% |
| Check-Cap Ltd. | -17.56 Million USD | -1062.05% |
| Twist Bioscience Corporation | -208.72 Million USD | 2.193% |
| DarioHealth Corp. | -59.42 Million USD | -243.529% |
| Fulgent Genetics, Inc. | -167.82 Million USD | -21.644% |
| Sera Prognostics, Inc. | -36.24 Million USD | -463.294% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -1929.264% |
| OPKO Health, Inc. | -188.86 Million USD | -8.094% |
| Medpace Holdings, Inc. | 282.81 Million USD | 172.186% |
| Neogen Corporation | -9.42 Million USD | -2066.957% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -1909.982% |
| Prenetics Global Limited | -62.72 Million USD | -225.473% |
| Mainz Biomed B.V. | -26.29 Million USD | -676.358% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -2472.114% |
| Trinity Biotech plc | -24.01 Million USD | -749.983% |
| Neuronetics, Inc. | -30.18 Million USD | -576.236% |
| Sotera Health Company | 51.37 Million USD | 497.363% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -2472.114% |